Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLL | Q9UGP5 | 1/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 7/20 | 0.50 |
| ▸ | DRD2 | P14416 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | DRD4 | P21917 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | HTR5A | P47898 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6804047 | 1.00 | POLL (0.62) | POLLCYP19A1HSD11B1HTR1ADRD2 | |
| SCHEMBL2818908 | 0.90 | POLL (0.55) | POLLCYP19A1HSD11B1KMT2ACA1 | |
| SCHEMBL24510645 | 0.81 | S1PR1 (0.52) | POLLHTR1ADRD2DRD3DRD4 | |
| SCHEMBL13518769 | 0.81 | POLL (0.47) | POLLCYP19A1HSD11B1HTR1ADRD2 | |
| SCHEMBL13616708 | 0.81 | POLL (0.49) | POLLDRD2ADRA1A | |
| SCHEMBL30715540 | 0.80 | CYP19A1 (0.48) | POLLCYP19A1HSD11B1HTR1ADRD2 | |
| SCHEMBL11087080 | 0.80 | ACHE (0.50) | POLLKMT2ATSHR | |
| SCHEMBL17014300 | 0.80 | HTR1A (0.55) | CYP19A1HSD11B1HTR1ADRD2DRD3 | |
| SCHEMBL29944713 | 0.79 | POLL (0.48) | POLLCYP19A1HSD11B1DRD2DRD3 | |
| SCHEMBL24873168 | 0.79 | CYP19A1 (0.50) | CYP19A1HSD11B1HTR1ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3568128-B1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIV KANSAS (US) | 2022-07-06 | — | — | EP | disclosed |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-02-23 | — | — | US | disclosed |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | UNIVERSITY OF KANSAS (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| EP-3568128-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | The University of Kansas (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | UNIVERSITY OF KANSAS | 2019-11-07 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-05-28 | — | — | US | disclosed |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | US | disclosed |
| US-4692445-A | ANTISECRETORY, ANTIULCEROGENIC AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1987-09-08 | — | — | US | disclosed |
| EP-0199781-A4 | BICYCLIC BENZENOID ALKYLENE AMINO THIENO AD3,4-d BDISOTHIAZOLE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES. | RORER INTERNAT OVERSEAS INC (US) | 1987-03-30 | — | — | EP | disclosed |
| US-4647559-A | ANTISECRETORY AND ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1987-03-03 | — | — | US | disclosed |
| US-4638001-A | ANTISECRETORY, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1987-01-20 | — | — | US | disclosed |
| EP-0199781-A1 | BICYCLIC BENZENOID ALKYLENE AMINO THIENO AD3,4-d BDISOTHIAZOLE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (a Delaware corporation) (US) | 1986-11-05 | — | — | EP | disclosed |
| US-4588719-A | ANTISCERETORY AGENTS, ANTIULCER AGENTS | WILLIAM H. RORER, INC. (US) | 1986-05-13 | — | — | US | disclosed |
| WO-1986002552-A1 | BICYCLIC BENZENOID ALKYLENE AMINO THIENO AD3,4-d BDISOTHIAZOLE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1986-05-09 | — | — | WO | disclosed |
| EP-0150192-A4 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INTERNAT OVERSEAS INC (US) | 1985-09-16 | — | — | EP | disclosed |
| EP-0150192-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INT OVERSEAS (US) | 1985-08-07 | — | — | EP | disclosed |
| WO-1984004247-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190337894-A1 | HSP90B N-TERMINAL ISOFORM-SELECTIVE INHIBITORS | HSP90AB1, HSP90AB2P, HSP90B1 | POLL 3655/4885CYP19A1 2565/4885HSD11B1 583/4885 |
| US-10927076-B2 | HSP90B N-terminal isoform-selective inhibitors | HSP90AB1, HSP90AB2P, HSP90B1 | POLL 3655/4885CYP19A1 2565/4885HSD11B1 583/4885 |
| US-10300062-B2 | Bicyclically substituted uracils and the use thereof | UNG, UMPS, TYMP | POLL 349/4885CYP19A1 1787/4885HSD11B1 2513/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | POLL 349/4885CYP19A1 1787/4885HSD11B1 2513/4885 |
| US-20180256576-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | POLL 349/4885CYP19A1 1787/4885HSD11B1 2513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.